Stopping Ozempic Increases Heart Attack and Stroke Risk
Stopping semaglutide or tirzepatide treatments for type 2 diabetes and obesity can reverse their cardiovascular benefits within months, according to a study published in BMJ Medicine. Researchers at Washington University School of Medicine in St. Louis found that interrupting GLP-1 drug therapy for as little as six months was associated with a meaningful increase in … Read more